Vaccine safety: Current and future challenges

Pediatric Annals

Volumn 27, Issue 7, 1998, Pages 445-455

  Chen, Robert T ^a   Hibbs, Beth ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DIS CONTR AND PREV   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

CLINICAL RESEARCH; DATA BASE; DRUG MONITORING; DRUG SAFETY; HUMAN; REVIEW; RISK ASSESSMENT; SIDE EFFECT; VACCINATION;

EID: 0031950458     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/0090-4481-19980701-11     Document Type: Review

References (69)

1. Chen RT, Rastogi SC, Mullen JR, et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine. 1994;12:542-550.
2. Duclos P. Surveillance des effets secondaires de la vaccination. Sante. 1994;4:215-220.
3. Gangarosa EJ, Galazka AM, Wolfe CR, Chen RT, Phillips LM, Gangarosa RE, Miller E. Impact of the anti-whole-cell pertussis vaccine movements. Lancet. 1997;351:356-361.
4. Galazka AM, Robertson SE, Oblapenko GP. Resurgence of diphtheria. Eur J Epidemiol. 1995;11:95-105.
5. Wilson GS. The hazards of immunization. London: Athlone Press, 1967.
6. Schumacher W. Legal/ethical aspects of vaccinations. Dev Biol Stand. 1979;43:435-438.
7. Pennisi E. Monkey virus DNA found in rate human cancers. Science. 1997;275:748-749.
8. Food and Drug Administration. Bovine-derived materials: Agency letters to manufacturers of FDA-regulated products. Federal Register. 1994;59:44591-44594.
9. Mathieu M, ed. Biologic Development: A Regulatory Overview. Waltham, MA: Paraxel, 1993.
10. Neustadt RE, Fineberg HV. The Swine Flu Affair: Decision-Making on a Slippery Disease. Washington, DC: US Government Printing Office, 1978.
11. Lloyd JC, Chen RT. The Urabe mumps vaccine: lessons in adverse event surveillance and response. Pharmacoepidemiology and Drug Safety. 1996;5:S45. Abstract.
12. Kimura M, Kuno-Sakai H, Yamazaki S, et al. Adverse event, associated with MMR vaccines in Japan. Acta Paediatrica Japonica. 1996;38:205-211.
13. Howson CP, Howe CJ, Fineberg HV, eds. Institute of Medicine. Adverse effects of pertussis and rubella vaccines: A report of the Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines. Washington, DC: National Academy Press, 1991.
14. Stratton KR, Howe CJ, Johnston RB, eds. Adverse events associated with childhood vaccines: Evidence bearing on causality. Washington, DC: National Academy Press, 1994.
15. Chen RT. Special methodological issues in pharmacoepidemiology studies of vaccine safety. In: Strom BL, ed. Pharmacoepidemiology. Sussex: John Wiley & Sons, 1994:581-594.
16. Fine PEM, Chen RT. Confounding in studies of adverse reactions to vaccines. Am J Epidemiol. 1992;136:121-135.
17. Rothman KJ, ed. Causal Inference. Chestnut Hill, MA: Epidemiology Resources, Inc., 1988.
18. Farrington CP, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet. 1995;345:567-569.
19. Ellenberg SS, Chen RT. The complicated task of monitoring vaccine safety. Public Health Reports. 1997;112:10-20.
20. Morris R, Halperin S, Dery P, et al. IMPACT monitoring network: a better mouse-trap. Can J Infect Dis. 1993;4:194-195.
21. Roberts JD, Roos LL, Poffenroth LA, et al. Surveillance of vaccine-related adverse events in the first year of life: A Manitoba cohort study. J Clin Epidemiol. 1996;49:51-58.
22. Chen RT, Glasser J, Rhodes P, et al. The Vaccine Safety Datalink Project: A New Tool for Improving Vaccine Safety Monitoring in the United States. Pediatrics. 1997;99:765-773.
23. Rosenthal KL, McVittie LD. The clinical testing of preventive vaccines. In: Mathieu M, ed. Biologic Development: A Regulatory Overview. Waltham, MA: Paraxel, 1993:119-130.
24. Pinichiero ME. Acellular pertussis vaccines: towards an improved safety profile. Drug Experience. 1996;15:311-324.
25. Global Programme on Vaccines and Immunization. Quality: the first consideration. Geneva: WHO/GPV/SAGE.97/WP.03.
26. Steinhoff MC, Reed GF, Decker MD, et al. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics. 1995;S567-570.
27. Niu MT, Rhodes P, Salive M, Lively T, Davis DM, Black S, et al. Comparative safety of two recombinant hepatitis b vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD). J Clin Epidemiol. 1998; In press.
28. Baraff LJ, Cody CL, Cherry JD. DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions, and dose. Pediatrics. 1984;73:31-36.
29. Rastogi SC, ed. International Workshop: Harmonization of Reporting of Adverse Events Following Vaccination. Rockville, MD: FDA/CBER, 1993.
30. Wiholm BE, Olsoon S, Moore N, Wood S. Spontaneous reporting systems outside the U.S. In: Strom BL, ed. Pharmacoepidemiology. Sussex: John Wiley & Sons, 1994:139-155.
31. Centers for Disease Control. National Childhood Vaccine Injury Act: Requirements for Permanent Vaccination Records and for Reporting of Selected Events after Vaccination. MMWR. 1988;37:197-200.
32. Stetler HC, Mullen JR, Brennan JP, Livengood JR, Orenstein WA, Hinman AR. Monitoring system for adverse events following immunization. Vaccine. 1987;5:169-174.
33. Braun MM, Ellenberg SS. Descriptive epidemiology of adverse events after immunization: reports to the Vaccine Adverse Event Reporting System (VAERS), 1991-1994. J Pediatr. 1997;131:529-535.
34. Fenichel GM, Lane DA, Livengood JR, Horwitz SJ, Menkes JH, Schwartz JF. Adverse events following immunization: assessing probability of causation. Pediatr Neurol. 1989;5:287-290.
35. Wassilak SGF, Sokhey J. Monitoring of adverse events following immunization in the Expanded Programme on Immunization. World Health Organization. 1991;WHO/EPl/GEN/91.2:1-29.
36. Kramer MS, Lane DA. Causal propositions in clinical research and practice. J Clin Epidemiol. 1992;45:639-649.
37. Mariner WK. Compensation programs for vaccine-related injury abroad: a comparative analysis. Saint Louis University Law Journal. 1987;31:599-654.
38. Forsey T, Mawn JA, Yates PJ, Bently ML, Minor PD. Differentiation of vaccine and wild mumps viruses using the polymerase chain reaction and dideoxinucleotide. J Gen Virol. 1990;71:987-990.
39. Henderson DA, Witte JJ, Morris L, Langmuir AD. Paralytic disease associated with oral polio vaccines. JAMA. 1964;190:153-160.
40. Ray WA, Griffin MR. Confounding in studies of adverse reactions to vaccines (letter). Am J Epidemiol. 1994;139:229.
41. Davis R, Vadheim C, Black S, et al. Immunization tracking systems: experience of the CDC Vaccine Safety Datalink sites. HMO Practice. 1997;11:13-17.
42. Black SB, Shinefield HR, and the Northern California Permanente Medical Care Program Department of Pediatrics Vaccine Study Group. b-CAPSA 1 Haemophilus influenzae, type b capsular polysaccharide vaccine safety. Pediatrics. 1987;79:321-325.
43. Williams JC, Goldenthal KL, Burns DL, Lewis BP Jr, eds. Combined vaccines and simultaneous administration: current issues and perspective. New York: New York Academy of Science, 1995.
44. Hinman AR, Orenstein WA. Public health considerations. In: Plotkin SA, Mortimer EA, eds. Vaccines. Philadelphia: WB Saunders; 1994:903-932.
45. Evans G. Vaccine liability and safety: a progress report. Pediatr Infect Dis J. 1996;15:477-478.
46. Walker AM, Jick H, Perera DR. et al. Neurologic events following diphtheriatetanus-pertussis immunization. Pediatrics. 1988;81:345-349.
47. Griffin MR, Ray WA, Mortimer EA, et al. Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus-pertussis vaccine. JAMA. 1990;263:1641-1645.
48. Fine PEM. Methodological issues in the evaluation and monitoring of vaccine safety. Ann NY Acad Sci. 1995;754:300-308.
49. Watson JC, Peter G. General immunization practices. In: Plotkin SA, Orienstein WA (eds). Vaccines (3rd ed.). Philadelphia: WB Saunders, 1998. In Press.
50. American Academy of Pediatrics. Active immunization. In: Peter G, ed 1997 Redbook: Report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village, IL: American Academy of Pediatrics, 1997:4-36.
51. US Department of Health and Human Services, Public Health Service, CDC. Vaccine management recommendations for handling and storage of selected biologicals. March 1991.
52. U.S. Department of Health and Human Services, Public Health service, CDC. Guidelines for vaccine packing and shipping. January 1997.
53. Weniger BG, Chen RT, Jacobsen SH, Sewell EC, Deuson R, Livengood JR, et al. Addressing the challenges to immunization practice with an economic algorithm for vaccine selection. Vaccine. 1998 (in press).
54. Zaffran M, Lloyd J, Clements J, Stilwell B. A drive to safer injections. Geneva: WHO/GPV/SAGE.97/WP.05, 1997.
55. Orenstein WA. DTP vaccine litigation. 1988. Am J Dis Child. 1990;144:517.
56. Institute of Medicine: Liability for the production and sale of vaccine. In: Vaccine supply and innovation. Washington, DC: National Academy Press, 1985;85-122.
57. Offit PM, Bell LM. What even parent should know about vaccines. New York: Simon & Schuster Macmillan Company, 1998:1.
58. Freed GL, Katz SL, Clark SJ. Safety of vaccinations miss America, the media, and public health. JAMA. 1996;276:1869-1872,1917-1918.
59. Institute of Medicine: Risk Communication and Vaccination, Workshop summary. Washington, DC: National Academy Press, 1997.
60. National Research Council. Improving risk communication. Washington, DC: National Academy Press, 1989.
61. Fischhoff B, Bostrom A, Jacobs-Quadrel M. Risk perceptions and communication. Annual Review of Public Health. 1993;14:182-203.
62. Hibbs BF, Wolfe S, Chen RT. Internet Web page perceptions of vaccine pharmacoepidemiology research: An analysis of vaccine safety concerns. Abstract 129. Abstracts of the 13th International Conference on Pharmacoepidemiology. Walt Disney World, Florida: August 24-27, 1997. Pharmacoepidemiology and Drug Safety. 1997;6(suppl 2):S60.
63. Meszaros JR, Asch DA, Baron J, Hershey JC, Kunreuther H, Schwartz-Buzaglo J. Cognitive processes and the decisions of some parents to forego pertussis vaccination for their children. J Clin Epidemiol. 1996;49:697-703.
64. Hance BJ, Chess C, Sandman P. Industry risk communication manual. Chelsea, MI: Lewis Publishers, 1990.
65. The National Childhood Vaccine Injury Act of 1986, at Section 2125 of the Public Health Service Act as codified at 42 U.S.C. § 300aa-(Suppl.1987).
66. O'Connor AM, Pennie RA, Dales RE. Framing effects on expectations, decisions, and side effects experienced: The case of influenza immunization. J Clin Epidemiol. 1996;49:1271-1276.
67. Baron J. The effect of normative beliefs on anticipated emotions. J Pers Soc Psychol. 1992;63:320-330.
68. Bostrom A. Vaccine risk communication: Lessons from risk perception, decision making and environmental risk communication research. Risk: Health, Safety & Environment. Spring 1997:173-200.
69. Binkin NJ, et al. Epidemiology of pertussis in a developed country with low vaccination coverate: the Italian experience. Pediatr Infect Dis J. 1992;11:653.